Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 8/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1288243 | 0.95 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL30523195 | 0.95 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL10319396 | 0.95 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL382821 | 0.95 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL92593 | 0.95 | PLK1 (0.51) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL1288242 | 0.95 | PLK1 (0.49) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936900 | 0.92 | PLK1 (0.43) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL6911026 | 0.88 | PLK1 (0.40) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL5936775 | 0.88 | PLK1 (0.40) | PLK1PLK2PLK3BRD4MAPK1 | |
| SCHEMBL31098106 | 0.87 | PLK1 (0.44) | PLK1PLK2PLK3BRD4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | PLK1 1/4885PLK2 19/4885PLK3 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.